Rapid Diagnostics for Rheumatoid Arthritis Study Published in Journal of Medical Economics Article
PHE recently published a new study in collaboration with Genalyte on the potential value of rapid, cloud-enabled, onsite laboratory testing for the diagnosis of rheumatoid arthritis. The study found that this technology could generate value of over $5,000 per evaluated patient-year. The study was led by PHE’s Kata Bognar, Jason Shafrin, Michelle Brauer, Lauren Zhao, and Bapu Jena.
To read the study abstract, please click the link below:
The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United States. Journal of Medical Economics, 2018. https://doi.org/10.1080/13696998.2018.1502191
In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.